Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Loss of KDM6A confers drug resistance in acute myeloid leukemia

14 Jun 2019

Abstract excerpt

Acute myeloid leukemia (AML) is an aggressive hematologic neoplasm resulting from the malignant transformation of myeloid progenitors. Despite intensive chemotherapy leading to initial treatment responses, relapse caused by intrinsic or acquired drug resistance represents a major challenge. Here, we report that histone 3 lysine 27 demethylase KDM6A (UTX) is targeted by inactivating mutations and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Epigenetics and DNA Methylation
Share to Histone Deacetylase Inhibitors Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31201358
DOI: 10.1038/s41375-019-0497-6

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Loss of KDM6A confers drug resistance in acute myeloid leukemiaPMID 31201358Read ↗

Evolution of Cytogenetically Normal Acute Myeloid Leukemia During Therapy and Relapse: An Exome Sequencing Study of 50 Patients.Semantic proximity Read ↗

KDM6 demethylases integrate DNA repair gene regulation and loss of KDM6A sensitizes human acute myeloid leukemia to PARP and BCL2 inhibitionSemantic proximity Read ↗

KDM6A loss sensitizes human acute myeloid leukemia to PARP and BCL2 inhibitionSemantic proximity Read ↗

Whole genome sequencing reveals the mutational landscape from disease diagnosis to relapse in patients with childhood acute myeloid leukaemia.Semantic proximity Read ↗

KDM6 demethylases integrate DNA repair gene regulation and loss of KDM6A sensitizes human acute myeloid leukemia to PARP and BCL2 inhibitionSemantic proximity Read ↗

Targeting lysine demethylase 6B ameliorates ASXL1 truncation–mediated myeloid malignancies in preclinical modelsSemantic proximity Read ↗

KDM6 and KDM4 histone lysine demethylases emerge as molecular therapeutic targets in human acute myeloid leukemiaSemantic proximity Read ↗

DEK oncogene expression during normal hematopoiesis and in Acute Myeloid Leukemia (AML)Semantic proximity Read ↗

Loss-of-function mutations in the histone methyltransferase EZH2 promote chemotherapy resistance in AMLSemantic proximity Read ↗

Targeting histone methylation to reprogram the transcriptional state that drives survival of drug-tolerant myeloid leukemia persistersSemantic proximity Read ↗

DISORDERED HISTONE METHYLATION IN HEMATOLOGICAL MALIGNANCIES THE CASE OF UTX/KDM6A.Semantic proximity Read ↗

The histone demethylase KDM5C functions as a tumor suppressor in AML by repression of bivalently marked immature genesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.